Under half of new cancer drugs increase survival by three months, study findsBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j30 (Published 04 January 2017) Cite this as: BMJ 2017;356:j30
- Susan Mayor
New cancer drugs vary greatly in improving overall survival and the quality of life they achieve when compared with previous treatments, says a study systematically evaluating health technology assessments of new anticancer agents approved from 2003 to 2013.1
“There are growing questions about the value gained from spending on what seem to be ever more expensive cancer medicines,” said the researchers, led by Elias Mossialos, of the London School of Economics and Political Science in London, UK.
The use of many different outcome measures …